AUGO vs SSRM

The deterministic health scores raise significant concerns, with a Piotroski F-Score of 4/9 indicating marginal financial health and no available Altman Z-Score to confirm safety from distress. Despite strong revenue growth and high operating margins, the company reports negative profit margins and ROE, alongside a dangerously high payout ratio of 780%, suggesting dividends are unsustainable. The stock trades at a steep valuation premium with a Price/Book of 17.69 and Forward P/E of 12.98, while recent earnings have consistently missed estimates—0 out of the last 4 beats and an average surprise of -86.59%. Although analyst consensus is 'strong_buy', price momentum appears disconnected from fundamentals, increasing downside risk.

With a Piotroski F-Score of 4/9, SSRM exhibits stable financial health, though the absence of an Altman Z-Score leaves a gap in bankruptcy risk quantification. The stock is currently priced at $31.75, trading at a premium to its Graham Number ($26.82) but significantly below its growth-based Intrinsic Value ($54.58). While the company shows explosive YoY earnings growth and a very low forward P/E of 6.13, the 'Çöpler Incident' noted in the 10-K represents a critical qualitative risk. Despite a bearish technical trend score, the fundamental valuation and analyst consensus suggest strong upside potential.